Drug Profile
Research programme: anticancer therapeutics - University of Maryland Greenebaum Cancer Center
Latest Information Update: 02 May 2007
Price :
$50
*
At a glance
- Originator University of Maryland Greenbaum Cancer Center
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Breast cancer; Cancer
Most Recent Events
- 20 Jan 2005 Preclinical trials in Breast cancer in USA (unspecified route)
- 20 Jan 2005 Preclinical trials in Cancer in USA (unspecified route)